Always up to date! 

Unser Ziel ist es, behandlungs- und anatomiespezifische Implantate zu entwickeln, die in Zusammenarbeit mit unseren Kunden zu berechenbaren und besseren Behandlungsergebnissen führen. Lesen Sie weiter, um mehr über unsere Lösungen, Prioritäten und Partnerschaften zu erfahren und darüber, wie wir mit unseren Teams nachhaltig Wert schaffen.

Seite 7 von 28.

Medartis reports 20% sales growth and makes further progress in strengthening its US organisation

  • Total net sales in the first half of 2022 increased by 20.1% or 18.0% excl. NSI (both in CER[1])
  • Strong growth in EMEA led to further market share gains and dynamic LATAM accelerated APAC...
Weiterlesen

Medartis completes acquisition of Nextremity Solutions Inc. and announces new US leadership

Basel, Switzerland, 3 May 2022 - Medartis Holding AG (SIX: MED) announced today that it has completed the acquisition of Nextremity Solutions Inc., a strategic commercialisation organisation located...

Weiterlesen

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Weiterlesen

Seite 7 von 28.